Why they built it
Akili started in 2011 to make software whose activity was itself treatment for attention issues, not just an app delivering educational material. Founder Eddie Martucci connected with neuroscientist Adam Gazzaley's research and added game-design and engineering experience from LucasArts. The team thought combining a therapeutic mechanism with an engaging game could create a treatment patients would use repeatedly.
How it ended
Akili was acquired rather than shut down for outright technology failure. Its 2023 revenue of $1.7 million remained small relative to $65.3 million in GAAP operating expenses, and it restructured toward consumer subscriptions. Virtual Therapeutics completed the acquisition on July 2, 2024 at $0.434 per common share, with Akili continuing as a subsidiary and its US products remaining available.
What went wrong
Most important first.
- 1
Revenue far below operating costs Monetization
For full-year 2023 Akili reported $1.7 million in total revenue, about $1.2 million from EndeavorOTC and $0.5 million from EndeavorRx, against $65.3 million in GAAP operating expenses.
- 2
Prescription model needed three parties to act Distribution
The initial strategy needed clinicians to prescribe, caregivers to obtain access, and children to complete treatment.
- 3
Consumer pivot traded sales teams for acquisition burden Distribution
In September 2023 Akili eliminated field-sales and market-access teams to favor consumer subscriptions, which removed the prescription step for the adult product but increased dependence on consumer awareness, acquisition and retention.
- 4
Narrow proven benefit limited value story Product-market fit
EndeavorRx improved the primary computer-based attention measure while secondary clinical and parent ratings did not all show significant differences, and the adult label says benefits may not extend to typical behavioral symptoms such as hyperactivity.
What could be different today
- On June 14, 2024 FDA cleared EndeavorOTC for adults with specified ADHD presentations and a demonstrated attention issue for use as part of a broader therapeutic program, allowing adult sales without a prescription.
- EndeavorRx and EndeavorOTC remain marketed in the US with October 2026 published prices of $99 for a 30-day prescription and $24.99 monthly, $99.99 per six months or $129.99 annually for adults, so a rebuild would compete directly with Akili itself.
- In June 2026 Shionogi launched ENDEAVORRIDE in Japan as an adjunctive pediatric treatment after a local Phase 3 trial and domestic approval, after Akili had in April 2024 exchanged all future royalties and certain milestone rights for $10.5 million alongside cancellation of a $5 million bond.